Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

VIVUS, Inc. (VVUS - Snapshot Report) is highly dependent on Qsymia (proposed trade name in the EU: Qsiva) for growth. The drug was launched in the U.S. in Sep 2012 as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index or BMI - 30 or more) or overweight (BMI - 27 or more) adults suffering from at least one weight-related co-morbid condition.

However, Qsymia has performed disappointingly since launch. Qsymia revenues in the second quarter of 2013 were $5.5 million compared with $4.1 million in the first quarter of 2013.

In order to boost Qsymia revenues, VIVUS is evaluating the drug for other indications including type II diabetes. Encouraging new data on Qsymia was published in an online edition of Diabetes Care. Data from the two-year SEQUEL study (n = 475) comparing Qsymia to placebo was analyzed by the publication. The study enrolled high-risk patents including overweight or obese patients with pre-diabetes or metabolic syndrome.

A considerable reduction in progression to type II diabetes and significant weight loss were observed in patients receiving Qsymia. Annualized incidence rate of type II diabetes declined by 70.5% and 78.7% at two Qsymia treated dosages of 7.5mg/46mg and 15mg/92mg, respectively, when compared to placebo.

The diabetes market is very crowded with key players like Merck (MRK - Analyst Report) and Novo Nordisk (NVO - Analyst Report) among others.

VIVUS, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Biopharma companies that currently look attractive include Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%